“Providing hope to patients in need worldwide by ensuring access to essential medicines to as many people as possible.”

This hope is contained in every tablet we produce and is reflected in all Access to Medicines initiatives conducted by the Eisai Group. These initiatives seek to ensure that medicines are readily available to patients in emerging and developing countries.

As part of our global human health care (hhc) mission, Eisai aims to fulfill the medical needs of patients around the world. We give first thought to patients and their families, and to increasing the benefits health care provides. This mission is our pride and joy. We will continue to promote Access to Medicines globally, supplying seemingly small tablets that have the potential to make a big impact on the futures of patients and their communities.

Each tablet contributes to both the health and future of every country

Eisai supports WHO’s Global Programme to Eliminate Lymphatic Filariasis.

Eisai Co., Ltd.
"Access to Medicines" is about ensuring that medicines and treatments are made available to the communities that need them.

**Eisai has been actively committed to this initiative for realizing greater access to medicines, and sees it as a long-term investment in emerging and developing countries.**

For people in many of these countries, the prevalence of neglected tropical diseases (NTDs) is a serious problem. More than one billion people in 149 countries and regions worldwide are estimated to be suffering from NTDs today. However, when compared to malaria, which is another kind of tropical disease, current efforts to combat NTDs remain inadequate.

**Greater access to medicines in emerging and developing countries**

**DEC Distribution by 2020**

Lymphatic filariasis is an NTD caused by parasitic worms known as filariae that are transmitted to humans by mosquito bites. If treatment is delayed, filariae can cause a range of clinical manifestations, including serious damage to lymphatic tissues, lymphedema of the limbs and genital disease, as well as elephantiasis, in which the legs of the individual swell up to resemble those of an elephant. These symptoms severely affect patients’ work prospects and quality of life.

It is estimated that more than 120 million people in 73 countries—mostly emerging or developing countries—suffer from lymphatic filariasis. Unfortunately, tablets of high-quality diethylcarbamazine (DEC), a lymphatic filariasis treatment, are currently in short supply globally. This poses a major obstacle to eliminating the disease.

For the elimination of lymphatic filariasis, **Eisai will supply up to 2.2 billion tablets free of charge from our Vizag Plant in India to 250 million people at risk in lymphatic filariasis endemic countries through the World Health Organization (WHO) until 2020.**

Through its DEC distribution activities, Eisai hopes to create a better tomorrow where people can fight the disease, regain their health and return to their jobs or gain new, productive jobs. This in turn contributes to the economy of each country and region.

**Eliminating Lymphatic Filariasis**

**Toward the elimination of lymphatic filariasis**

**Greater Access to Medicines**

*WHO has set the goal of eliminating lymphatic filariasis by 2020. (DEC distribution countries as of April 2017)*

**WHO African Region**
- Gambia
- Kenya
- Comoros
- Madagascar
- Sao Tome and Principe
- Zambia
- Zimbabwe

**WHO Eastern Mediterranean Region**
- Egypt

**WHO South-East Asia Region**
- Indonesia
- Bangladesh
- Myanmar
- Nepal
- Timor-Leste

**WHO Western Pacific Region**
- Fiji
- French Polynesia
- Lao PDR
- Malaysia
- Papua New Guinea
- Samoa
- Micronesia (FSM)
- Tuvalu
- Kiribati

**WHO Region of the Americas**
- Brazil
- Dominican Republic
- Guyana
- Haiti

---

**No. of affected patients: 120 million**

**No. of affected countries: 73**